NCT06513234View on ClinicalTrials.gov

Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone Lymphomas

PHASE2RecruitingINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

July 11, 2024

Primary Completion Date

June 21, 2026

Study Completion Date

June 21, 2029

Conditions
Marginal Zone Lymphoma
Interventions
DRUG

Orelabrutinib and obinutuzumab

Orelabrutinib and obinutuzumab 6cycles ;orelabrutinib 150mg

Trial Locations (1)

300020

RECRUITING

China Institute of Hematology and Blood Diseases Hospital ,Chinese Academy of Medical Sciences, Tianjin

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER